Cited by 577Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease PreventionEicosanoids and Hypertension Pharmacology

Strategies to increase nitric oxide signalling in cardiovascular disease

Lundberg, Jon O., Gladwin, Mark T., Weitzberg, Eddie·2015·Nature Reviews Drug Discovery

Abstract

Nitric oxide (NO) is a key signalling molecule in the cardiovascular, immune and central nervous systems, and crucial steps in the regulation of NO bioavailability in health and disease are well characterized. Although early approaches to therapeutically modulate NO bioavailability failed in clinical trials, an enhanced understanding of fundamental subcellular signalling has enabled a range of novel therapeutic approaches to be identified. These include the identification of: new pathways for enhancing NO synthase activity; ways to amplify the nitrate-nitrite-NO pathway; novel classes of NO-donating drugs; drugs that limit NO metabolism through effects on reactive oxygen species; and ways to modulate downstream phosphodiesterases and soluble guanylyl cyclases. In this Review, we discuss these latest developments, with a focus on cardiovascular disease.

Integrity signals

Registry

Crossref · 10.1038/nrd4623

Cites

270 of 270 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Lundberg, J. O., Gladwin, M. T., & Weitzberg, E.
Affiliations
  • Karolinska Institutet (SE)
  • University of Pittsburgh (US)
Corresponding author
  • Lundberg, Jon O.
  • Gladwin, Mark T.
  • Weitzberg, Eddie
Venue
Nature Reviews Drug Discovery
Published
2015-08-07
Volume
14
Issue
9
Pages
623-641
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W1119734502
Cited by
576
References
269
Citations by year
2026: 27 · 2025: 55 · 2024: 48 · 2023: 46 · 2022: 69 · 2021: 55 · 2020: 65 · 2019: 46 · 2018: 62 · 2017: 57 · 2016: 44 · 2015: 2
FWCI
6.72
Type
journal article
Language
en
Open access
closed
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (P01HL103455, T32HL007563, R01HL125886, R01HL098032, T32HL110849)
Topics
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
nitric oxide signaling, nitric oxide bioavailability, cardiovascular disease, nitric oxide synthase, nitrate-nitrite-nitric oxide pathway, reactive oxygen species, phosphodiesterase, soluble guanylate cyclase
MeSH terms
Animals, Cardiovascular Diseases, Humans, Nitric Oxide, Signal Transduction, Reactive Oxygen Species, Risk Reduction Behavior

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review